Send me real-time posts from this site at my email

Watchlist Update: 1-17-2019 - Teladoc - TDOC - Analyst comments

Teladoc analyst commentary at Jefferies - $TDOC

Teladoc catalysts give reason to own stock now, says Jefferies. Jefferies analyst Sean Dodge says his firm's updated market share analysis continues to show Teladoc as the dominant vendor. SimilarWeb data points to BetterHelp usage down quarter-over-quarter in November but stabilizing in December and up in January, Dodge tells investors in a research note. There are "multiple upcoming catalysts, giving investors a reason to own the stock now," says the analyst. He points out Teladoc shares are still down over 30% from their late-September highs. Dodge keeps a Buy rating on the stock with a $95 price target, which represents 57% upside potential.

Read more at: (source)
https://thefly.com/landingPage...


* This stock has been on our trading list for a while now. Will continue to look for trades in this name. *

Tiger's Take: "A good long term play in the medical field."


$TDOC, TELADOC HEALTH INC / H1


Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions.

Follow us and check back occasionally for additional articles or posts.